CervoMed's RewinD-LB Phase 2b trial for neflamapimod in dementia with Lewy bodies failed to meet primary and key secondary endpoints. The trial's topline analysis revealed suboptimal plasma drug ...

The US Food and Drug Administration (FDA) has granted orphan drug designation to CervoMed’s lead investigational therapy neflamapimod for the treatment of frontotemporal dementia, a rare ...

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB. The Boston clinical-stage ...

“We are pleased to have received Orphan Drug Designation as it implicitly recognizes the scientific rationale and potential for neflamapimod to treat this debilitating condition. Patients ...

The drug, neflamapimod, did not achieve the trial's main goal of significantly reducing symptoms of dementia versus a placebo, but the company said it believed the treatment had potential and ...

(RTTNews) - CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies or DLB failed to demonstrate ...

There are no approved treatments. Boston-based CervoMed (CRVO) said the Phase 2b trial of its neflamapimod did not meet significant statistical thresholds for its primary endpoint of a change in ...

“Obviously, we are disappointed with these results, particularly given our prior clinical experience with neflamapimod in patients with early-stage DLB and we are investigating the reasons for ...

The p38MAP kinase alpha enzyme inhibitor neflamapimod missed its primary and secondary endpoints in a phase II study of dementia with Lewy bodies, CervoMed said. Neurodegeneration in the cortical ...

CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy ...

“Obviously, we are disappointed with these results, particularly given our prior clinical experience with neflamapimod in patients with early-stage DLB and we are investigating the reasons for the ...